BECAS
FERREYRA COMPAGNUCCI Malena MarÍa
artículos
Título:
Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273
Autor/es:
CARLA A. PASCUALE; AUGUSTO VARESE; DIEGO S OJEDA; MARINA E. PASINOVICH; LAURA LÓPEZ; ANDRÉS H ROSSI; PAMELA E RODRIGUEZ; ESTEBAN A. MIGLIETTA; LABORATORIO SEVA GROUP; IGNACIO MAZZITELLI; FACUNDO DI DIEGO GARCIA; LAUTARO SANCHEZ; SANTIAGO OVIEDO ROUCO; MARÍA MORA GONZALEZ LOPEZ LEDESMA; JUAN PABLO ZURANO; BIANCA MAZZITELLI; GRACIELA SCRUZZI; PAULA BARBERO; DIEGO CARDOZO; SANDRA GALLEGO; MARIEL BORDA; MIGUEL DÍAZ; MINISTERIO DE SALUD DE LA PROVINCIA DE CÓRDOBA GROUP; UNC-FAC. CS. MÉDICAS-INVIV GROUP; FRANCISCO RIDAO; ANGELA BRIGIDO ROSALES; MINISTERIO DE SALUD DE LA PROVINCIA DE LA RIOJA GROUP; JORGE BOHN; JUAN M. TALIA; MARÍA E. DIANGELO; MARÍA A LACAZE; MINISTERIO DE SALUD DE LA PROVINCIA DE SAN LUIS GROUP; BALANZINO AIME; SEBASTIAN ISAAC GUTIERREZ; REGINA ERCOLE; ROSANA TORO; LORENA TAU; LAURA DELAPLACE; MALENA FERREYRA COMPAGNUCCI; UNIVERSIDAD NACIONAL DE LA PLATA GROUP; CELESTE SARTORI; ISABEL DESIMONE; CECILIA ECHEGOYEN; PILAR VELAZQUEZ ; CLARISA TESTA; MINISTERIO DE SALUD DE LA PROVINCIA DE BUENOS AIRES
Revista:
Cell Reports Medicine
Editorial:
Cell Press
Referencias:
Año: 2022
ISSN:
2666-3791
Resumen:
Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational strategy to rapidly increase vaccination coverage in many regions of the world. Although data regarding messenger RNA (mRNA) and ChAdOx1 vaccine combinations are available, there is limited information about the combination of these platforms with other vaccines widely used in developing countries, such as BBIBP-CorV and Sputnik V. Here, we assess the immunogenicity and reactogenicity of 15 vaccine combinations in 1,314 participants. We evaluate immunoglobulin G (IgG) anti-spike response and virus neutralizing titers and observe that a number of heterologous vaccine combinations are equivalent or superior to homologous schemes. For all cohorts in this study, the highest antibody response is induced by mRNA-1273 as the second dose. No serious adverse events are detected in any of the schedules analyzed. Our observations provide rational support for the use of different vaccine combinations to achieve wide vaccine coverage in the shortest possible time.
